Skip to main content

Advertisement

Table 3 Three years evolution of GnRHa treated and untreated patients with EP

From: Higher prevalence of obesity and overweight without an adverse metabolic profile in girls with central precocious puberty compared to girls with early puberty, regardless of GnRH analogue treatment

  Baseline 1 yr 2 yrs 3 yrs
  Treated Untreated Treated Untreated Treated Untreated Treated Untreated After Tx
CA (yr) 8.9 ± 0.6 8.8 ± 0.5 9.9 ± 0.6 9.8 ± 0.6 10.8 ± 0.7 10.7 ± 0.6 11.6 ± 0.7 11.5 ± 0.5 11.8 ± 0.4
Weight (z-score) 0.3 ± 0.7* 0.9 ± 0.6 0.1 ± 08* 0.9 ± 0.3 0.2 ± 0.9* 0.9 ± 0.4 0.1 ± 0.9* 0.9 ± 0.5** -0.1 ± 1.1
BMI (z-score) 0.4 ± 0.7 0.9 ± 0.6 0.3 ± 0.8 0.8 ± 0.5 0.4 ± 0.9 0.7 ± 0.6 0.3 ± 1.2 0.8 ± 0.6 0 ± 0.8
Ob/over (%) 29 40 14 15 33 32 28.6 27 0
Obesity (%) 0 15 0 5 0 0 0 9 0
Overweight (%) 29 25 14 10 33 32 28.6 18 0
Glycemia (mg/dl) 79 ± 9.9 81.3 ± 11.1 89 ± 15.3 83.3 ± 9.7 84.3 ± 6.1 81.2 ± 8.6 84 ± 5.7 83 ± 6.4 83
Total-C (mg/dl) 195 ± 36.4 178.3 ± 35.5 184.8 ± 37.1 183.5 ± 33.8 186.8 ± 25 187.7 ± 41.8 133.5 ± 0.7 139.4 ± 37.6 123
LDL-C (mg/dl) 125 ± 38.4 113.2 ± 17.6 117.5 ± 42.8 131.5 ± 28.4 89.6 ± 66 105.8 ± 21.8 70.8 ± 5.1 83.7 ± 6.5 N.A
HDL-C (mg/dl) 50.6 ± 1.8 53 ± 9.1 51.3 ± 4.8 42.1 ± 7.4 47.7 ± 2.5 56 ± 24.3 49 ± 1.4 34.3 ± 4 N.A
TGR (mg/dl) 92.5 ± 30.9 113.4 ± 58.3 110 ± 43 73.9 ± 18 88 ± 18.5 85 ± 36 68.5 ± 14.9 96.5 ± 36.6 N.A.
TGR/HDL-C ratio 1.8 ± 0.6 1.5 ± 0.5 2.2 ± 1.3 1.9 ± 0.5 1.8 ± 0.3 1.5 ± 1 1.4 ± 0.3 2 ± 0.5 N.A.
  1. Data are expressed as mean ± SDS. SDS denotes the standard-deviation score for age and sex.
  2. After Tx, after treatment; CA, Chronological age; BMI, body mass index; Ob/Over, obesity and overweight rate; Total-C, total cholesterol; LDL-C, Low density lipoprotein cholesterol; HDL-C, High density lipoprotein cholesterol; TGR, Triglycerides.
  3. *p <0.05 treated vs. untreated patients.
  4. **p 0.03 untreated vs. patients after stop treatment.